In March, the FDA warned that Zocor users had an increased risk of rhabdomyolysis when taking the drug at high doses of 80 mg. While all statins carry some risk of the muscle injury, the FDA’s report was the first time a dose-specific connection had been made to a particular drug. Symptoms of rhabdomyolysis from Zocor could include muscle cramps, tenderness, stiffness, pain or spasms. The illness is usually reported in patients over 65 years of age or those who have renal impairment or uncontrolled hypothyroidism.
Zocor (simvastatin) is a synthetic statin developed by Merck & Co., which is now available as a generic. Before patent protections expired in 2005, it was Merck’s best-selling drug and the second best selling cholesterol lowering drug in the world, bringing in $4.3 billion in 2005.